Recently, the journal Signal Transduction and Targeted Therapy (STTT), co-published by State Key Laboratory of Biotherapy of West China Hospital, Sichuan University and Springer-Nature Publishing Group, was officially included by Science Citation Index (SCI) with its first impact factor to be issued this June.
Inaugurated in 2016, the journal is an English periodical focusing on biomedicine sponsored by the scheme of enhancing international influence of Chinese science and technology periodicals. It aims to be an internationally famous journal in signal transduction and targeted therapy, publishing researches in tumor and other major diseases. Here is its official website: http://www.nature. com/sigtrans
So far, led by Prof. Wei Yuquan, academician of Chinese Academy of Sciences, from West China Hospital, Prof. Zhang Kang from University of California San Diego, Prof. Carlo M. Croce from Ohio State University, the editorial team is composed of 87 members from 10 countries like the United States, Australia, Germany, France, Italy and Japan. West China Hospital, Sichuan University, as the major organizer, provide with disciplinary platforms and talent support.
Till now, STTT has been included by SCI, Scopus, PubMed Central (PMC), Directory of Open Access Journals (DOAJ) , BIOSIS and other important international database.
According to annual report of World Academic Journal Citation Index (WAJCI) by China Research Center for Scientific Literature Measurement and Evaluation, STTT was among the eighty Chinese journals as Q1 Journals of world reputation. In addition, two papers from STTT were included in 100 excellent Chinese medical papers in 2018. One of them, The role of MicroRNAs in human cancer by Profs. Yong Peng and Carlo M Croce has been cited by more than 180 times since March 2016.